Renalytix Future Growth
Future criteria checks 2/6
Renalytix is forecast to grow earnings and revenue by 6.7% and 126.2% per annum respectively.
Key information
6.7%
Earnings growth rate
n/a
EPS growth rate
| Healthcare Services earnings growth | 30.1% |
| Revenue growth rate | 126.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2026 | 39 | -25 | N/A | N/A | 1 |
| 6/30/2025 | 10 | -26 | N/A | N/A | 1 |
| 9/30/2024 | 2 | -28 | -24 | -24 | N/A |
| 6/30/2024 | 2 | -33 | -30 | -30 | N/A |
| 3/31/2024 | 2 | -37 | -31 | -31 | N/A |
| 12/31/2023 | 2 | -42 | -36 | -36 | N/A |
| 9/30/2023 | 3 | -44 | -36 | -36 | N/A |
| 6/30/2023 | 3 | -46 | -34 | -34 | N/A |
| 3/31/2023 | 4 | -40 | -40 | -40 | N/A |
| 12/31/2022 | 4 | -42 | -37 | -37 | N/A |
| 9/30/2022 | 3 | -47 | -43 | -43 | N/A |
| 6/30/2022 | 3 | -45 | -47 | -46 | N/A |
| 3/31/2022 | 3 | -50 | -38 | -37 | N/A |
| 12/31/2021 | 2 | -44 | -38 | -38 | N/A |
| 9/30/2021 | 2 | -38 | -30 | -28 | N/A |
| 6/30/2021 | 1 | -35 | -30 | -28 | N/A |
| 3/31/2021 | 1 | -28 | -28 | -26 | N/A |
| 12/31/2020 | 0 | -20 | -23 | -22 | N/A |
| 9/30/2020 | N/A | -16 | -20 | -18 | N/A |
| 6/30/2020 | N/A | -10 | -11 | -10 | N/A |
| 3/31/2020 | N/A | 28 | -6 | -7 | N/A |
| 12/31/2019 | N/A | -8 | -4 | -5 | N/A |
| 9/30/2019 | N/A | -5 | -8 | -4 | N/A |
| 6/30/2019 | N/A | -42 | -17 | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2O9 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2O9 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2O9 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2O9's revenue (126.2% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 2O9's revenue (126.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2O9's Return on Equity is forecast to be high in 3 years time